ISODIOL INTERNATIONAL INC ORDINARY SHAR (OTCMKTS:ISOLF) Could Improve Your Long Portfolio After Less Shorts Reported

The stock of ISODIOL INTERNATIONAL INC ORDINARY SHAR (OTCMKTS:ISOLF) registered a decrease of 23.53% in short interest. ISOLF’s total short interest was 6,500 shares in September as published by FINRA. Its down 23.53% from 8,500 shares, reported previously.

The stock increased 1.11% or $0.0027 during the last trading session, reaching $0.2467. About 8,455 shares traded. Isodiol International Inc. (OTCMKTS:ISOLF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Isodiol International Inc. develops and makes consumer products in Canada and the United States. The company has market cap of $12.22 million. It offers functional beverages, anti-aging luxury skin care products, and cannabinoid nutraceuticals. It currently has negative earnings. The firm distributes its products to health food stores, specialty markets, health professional offices, spas, and cannabis dispensaries, as well as directly to consumer channels.

More notable recent Isodiol International Inc. (OTCMKTS:ISOLF) news were published by: Marketwatch.com which released: “Isodiol International Inc. – MarketWatch” on October 18, 2017, also Seekingalpha.com with their article: “Isodiol: The Investment That Went Horribly Wrong – Seeking Alpha” published on December 21, 2018, Seekingalpha.com published: “Liberty Health Sciences: Surviving And Thriving After Aphria – Seeking Alpha” on September 18, 2018. More interesting news about Isodiol International Inc. (OTCMKTS:ISOLF) were released by: Midasletter.com and their article: “Isodiol International Ord (CNSX:ISOL) Technical Take, Assorted Tidbits Heading Into Tomorrow’s Re-Open – Midas Letter” published on April 16, 2018 as well as Seekingalpha.com‘s news article titled: “Charlotte’s Web: Weak Q3 Can’t Hide Its Potential – Seeking Alpha” with publication date: December 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.